Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

Diabetes Mellitus Clinical Trial

— COMPLEMENT  

Official title:

A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00672919
• Other study ID #: 01-03-TL-OPI-523
• Secondary ID: U1111-1115-8914
• Status: Completed
• Phase: Phase 4
• First received: May 2, 2008
• Last updated: February 27, 2012
• Start date: November 2003
• Est. completion date: August 2004

Study information

• Verified date: February 2012
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.

Description:

Diabetes mellitus is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes has a genetic predisposition, but lifestyle, physical habits and age play important roles in determining its time of onset and severity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic (liver) and peripheral-tissue cells to circulating insulin (ie, insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (ie, insulin deficiency due to beta-cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 15.7 million people have diabetes, with type 2 diabetes occurring in approximately 90 to 95% of cases.

Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes. Recently introduced drugs for diabetes therapy are the thiazolidinedione class. Thiazolidinediones increase glucose utilization, decrease gluconeogenesis and increase glucose disposal through an incompletely understood mechanism but one associated with binding of the drug to receptors known as peroxisomal proliferator-activated receptors.

Thiazolidinediones are peroxisomal proliferator-activated receptor agonists reducing insulin resistance in muscle cells, adipose (fat) tissue, and hepatic cells (inhibiting hepatic gluconeogenesis) with no direct impact on insulin secretion. Thus peroxisomal proliferator-activated receptor agonists improve glycemic control and result in reduced levels of circulating insulin. Peroxisomal proliferator-activated receptors are found in various tissues important for insulin action, with the greatest concentration of these receptors is in adipose tissue.

Pioglitazone is a peroxisomal proliferator-activated receptor agonist developed by Takeda Chemical Industries, Ltd. (Osaka, Japan).

Participation in this study is anticipated to be approximately 20 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 305
• Est. completion date: August 2004
• Est. primary completion date: August 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosed with type 2 diabetes mellitus

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study

• Has been taking a stable dose of rosiglitazone for greater than 90 days prior to screening.

• Has a triglyceride level greater than 200 mg per dL but less than 1000 mg per dL.

• Has been taking a stable statin therapy for greater than 90 days prior to screening.

• Has a glycosylated hemoglobin less than 10.5%.

Exclusion Criteria:

• Type 1 diabetes mellitus.

• Treated with Gemfibrozil within 90 days of screening.

• Previous history of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug.

• The subject has an alanine aminotransaminase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.

• Male subjects who have serum creatinine greater than 2.0 mg per dL and female subjects with serum creatinine greater than1.8 mg per dL.

• Unexplained microscopic hematuria greater than plus 1 confirmed by repeat testing.

• Male subjects who have hemoglobin less than 10.5 g per dL and female subjects who have hemoglobin less than 10.0 g per dL.

• Significant cardiovascular disease including, but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV

• Currently is participating in another investigational study or has participated in an investigational study within the past 30 days.

• Any other serious disease or condition that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.

• Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• Glucocorticoids (eg. prednisone, cortisone, hydrocortisone, dexamethasone) with the exception of a topical glucocorticoid agent.

• Gemfibrozil

• Steroid-joint injections.

• Thiazolidinediones with the exception of the study medication.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Drug:
• Pioglitazone
Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Puerto Rico, 

References & Publications (1)

Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, Demissie S, Fleck PR. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006 May;3(1):39-44. Erratum in: Diab Vasc Dis Res. 2006 Sep;3(2):71. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Triglyceride Levels		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in Total Cholesterol		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in direct Low Density Lipoprotein cholesterol		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in High Density Lipoprotein cholesterol		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in apolipoprotein B (apoB)		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in apolipoprotein A1 (apoA1)		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in Free Fatty Acids		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in Lipid Fractionation		Weeks 8 and 17 or Final Visit	No
Secondary	Change from Baseline in C-reactive Protein		Weeks 8 and 17 or Final Visit	No

External Links

•   ACTOS® Package Insert
•   FDA Safety Alerts and Recalls